156 related articles for article (PubMed ID: 25008438)
21. Cutaneous adverse events associated with vemurafenib in patients with metastatic melanoma: practical advice on diagnosis, prevention and management of the main treatment-related skin toxicities.
Sinha R; Edmonds K; Newton-Bishop JA; Gore ME; Larkin J; Fearfield L
Br J Dermatol; 2012 Nov; 167(5):987-94. PubMed ID: 22913467
[TBL] [Abstract][Full Text] [Related]
22. Comparative profile of cutaneous adverse events: BRAF/MEK inhibitor combination therapy versus BRAF monotherapy in melanoma.
Sanlorenzo M; Choudhry A; Vujic I; Posch C; Chong K; Johnston K; Meier M; Osella-Abate S; Quaglino P; Daud A; Algazi A; Rappersberger K; Ortiz-Urda S
J Am Acad Dermatol; 2014 Dec; 71(6):1102-1109.e1. PubMed ID: 25440439
[TBL] [Abstract][Full Text] [Related]
23. Vemurafenib-induced radiation recall dermatitis: case report and review of the literature.
Conen K; Mosna-Firlejczyk K; Rochlitz C; Wicki A; Itin P; Arnold AW; Gross M; Zimmermann F; Zippelius A
Dermatology; 2015; 230(1):1-4. PubMed ID: 25472806
[TBL] [Abstract][Full Text] [Related]
24. Dermatological approach to vemurafenib skin toxicity: a single centre experience.
Fava P; Marra E; Astrua C; Brizio M; Cavaliere G; Quaglino P; Fierro MT; Savoia P
G Ital Dermatol Venereol; 2016 Feb; 151(1):25-31. PubMed ID: 25296968
[TBL] [Abstract][Full Text] [Related]
25. Eruptive squamous cell carcinomas after vemurafenib therapy.
Mays R; Curry J; Kim K; Tsai K; Arora A; Khan F; Ramirez-Fort M; Ciurea A
J Cutan Med Surg; 2013; 17(6):419-22. PubMed ID: 24138980
[TBL] [Abstract][Full Text] [Related]
26. Vemurafenib-related cutaneous side effects ameliorated by acitretin.
Chon SY; Sambrano BL; Geddes ER
J Drugs Dermatol; 2014 May; 13(5):586-8. PubMed ID: 24809883
[TBL] [Abstract][Full Text] [Related]
27. Vemurafenib-induced neutrophilic panniculitis.
Monfort JB; Pagès C; Schneider P; Neyns B; Comte C; Bagot M; Vignon-Pennamen MD; Viguier M; Lebbé C
Melanoma Res; 2012 Oct; 22(5):399-401. PubMed ID: 22828248
[TBL] [Abstract][Full Text] [Related]
28. Cutaneous adverse events in patients treated with BRAF inhibitor-based therapies for metastatic melanoma for longer than 52 weeks.
Anforth R; Carlos G; Clements A; Kefford R; Fernandez-Peñas P
Br J Dermatol; 2015 Jan; 172(1):239-43. PubMed ID: 25040674
[TBL] [Abstract][Full Text] [Related]
29. [Vemurafenib-induced toxic epidermal necrolysis].
Wantz M; Spanoudi-Kitrimi I; Lasek A; Lebas D; Quinchon JF; Modiano P
Ann Dermatol Venereol; 2014 Mar; 141(3):215-8. PubMed ID: 24635957
[TBL] [Abstract][Full Text] [Related]
30. Vemurafenib in patients with BRAF(V600) mutated metastatic melanoma: an open-label, multicentre, safety study.
Larkin J; Del Vecchio M; Ascierto PA; Krajsova I; Schachter J; Neyns B; Espinosa E; Garbe C; Sileni VC; Gogas H; Miller WH; Mandalà M; Hospers GA; Arance A; Queirolo P; Hauschild A; Brown MP; Mitchell L; Veronese L; Blank CU
Lancet Oncol; 2014 Apr; 15(4):436-44. PubMed ID: 24582505
[TBL] [Abstract][Full Text] [Related]
31. Vemurafenib: in unresectable or metastatic melanoma.
Keating GM
BioDrugs; 2012 Oct; 26(5):325-34. PubMed ID: 22946753
[TBL] [Abstract][Full Text] [Related]
32. Reaccion acneiforme noduloquistica secundaria a vemurafenib con buena respuesta a isotretinoina oralSevere acneiform eruption associated with vemurafenib with response to isotretinoin.
Elosua-Gonzalez M; Lopez-Estebaranz JL; Garcia-Zamora E; Vela-Ganuza M; Rodrigez-Vasquez X
Dermatol Online J; 2018 Aug; 24(8):. PubMed ID: 30677858
[TBL] [Abstract][Full Text] [Related]
33. Prospective study of cutaneous side-effects associated with the BRAF inhibitor vemurafenib: a study of 42 patients.
Boussemart L; Routier E; Mateus C; Opletalova K; Sebille G; Kamsu-Kom N; Thomas M; Vagner S; Favre M; Tomasic G; Wechsler J; Lacroix L; Robert C
Ann Oncol; 2013 Jun; 24(6):1691-7. PubMed ID: 23406731
[TBL] [Abstract][Full Text] [Related]
34. Vemurafenib-induced pityriasis amiantacea: a case report.
Bilgiç Ö
Cutan Ocul Toxicol; 2016 Dec; 35(4):329-31. PubMed ID: 26513697
[TBL] [Abstract][Full Text] [Related]
35. Acute kidney injury in patients with severe rash on vemurafenib treatment for metastatic melanomas.
Regnier-Rosencher E; Lazareth H; Gressier L; Avril MF; Thervet E; Dupin N
Br J Dermatol; 2013 Oct; 169(4):934-8. PubMed ID: 23909652
[TBL] [Abstract][Full Text] [Related]
36. Improved overall survival in melanoma with combined dabrafenib and trametinib.
Robert C; Karaszewska B; Schachter J; Rutkowski P; Mackiewicz A; Stroiakovski D; Lichinitser M; Dummer R; Grange F; Mortier L; Chiarion-Sileni V; Drucis K; Krajsova I; Hauschild A; Lorigan P; Wolter P; Long GV; Flaherty K; Nathan P; Ribas A; Martin AM; Sun P; Crist W; Legos J; Rubin SD; Little SM; Schadendorf D
N Engl J Med; 2015 Jan; 372(1):30-9. PubMed ID: 25399551
[TBL] [Abstract][Full Text] [Related]
37. Vemurafenib-associated neutrophilic panniculitis: An emergent adverse effect of variable severity.
Maldonado-Seral C; Berros-Fombella JP; Vivanco-Allende B; Coto-Segura P; Vazquez-Lopez F; Perez-Oliva N
Dermatol Online J; 2013 Apr; 19(4):16. PubMed ID: 24021375
[TBL] [Abstract][Full Text] [Related]
38. Ocular toxicity in BRAF mutant cutaneous melanoma patients treated with vemurafenib.
Choe CH; McArthur GA; Caro I; Kempen JH; Amaravadi RK
Am J Ophthalmol; 2014 Oct; 158(4):831-837.e2. PubMed ID: 25036880
[TBL] [Abstract][Full Text] [Related]
39. [Cellular and molecular mechanisms of carcinogenic side effects and resistance to BRAF inhibitors in metastatic melanoma with BRAFV600 mutation: state of the knowledge].
Capovilla M
Ann Pathol; 2013 Dec; 33(6):375-85. PubMed ID: 24331719
[TBL] [Abstract][Full Text] [Related]
40. Vemurafenib and radiosensitization.
Boussemart L; Boivin C; Claveau J; Tao YG; Tomasic G; Routier E; Mateus C; Deutsch E; Robert C
JAMA Dermatol; 2013 Jul; 149(7):855-7. PubMed ID: 23699661
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]